ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SNG Synairgen Plc

4.755
0.105 (2.26%)
23 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.105 2.26% 4.755 4.52 4.99 - 189,060 16:35:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.53 9.36M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.65p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.36 million. Synairgen has a price to earnings ratio (PE ratio) of -0.53.

Synairgen Share Discussion Threads

Showing 21401 to 21424 of 99175 messages
Chat Pages: Latest  859  858  857  856  855  854  853  852  851  850  849  848  Older
DateSubjectAuthorDiscuss
13/8/2020
13:45
yet another final - thanks for posting. Do you know who produced that peer summary?
dibs61
13/8/2020
12:38
Just a quote from one of the peers re results:This is a phase 2 study where limited numbers of patients are enrolled in order to quickly acquire enough data to analyse whether the drug has beneficial effects. In such studies, one usually looks across the whole range of results, rather than putting excessive focus on the primary endpoint; this allows us to understand whether the effects are consistent or could be spurious false positive artefacts due to a small sample size. It is extremely encouraging to see positive results across different endpoints, and in the subgroup of more severely affected individuals who needed oxygen at the time of hospital admission. The most important result appears to be a reduction in the number of patients requiring ventilation. While some caution should be applied until we see the full publication of data, these results suggest that interferon beta urgently warrants further evaluation as a treatment for COVID-19.So positive results ACROSS the different endpoints.... Very heartening
yet another final
13/8/2020
12:30
Still looks like there's a buy order in the market...... just an observation!!
nortic 007
Chat Pages: Latest  859  858  857  856  855  854  853  852  851  850  849  848  Older

Your Recent History

Delayed Upgrade Clock